Avtor/Urednik		Zakotnik, Branko; Vodnik-Cerar, Alenka
Naslov		Febrialna nevtropenija kot posledica specifičnega onkološkega zdravljenja
Prevedeni naslov		Febrile neutropenia and specific treatment in oncology
Tip		članek
Vir		Med Razgl
Vol. in št.		Letnik 35, št. Suppl 7
Leto izdaje		1996
Obseg		str. 7-14
Jezik		slo
Abstrakt		Besides tumor celis, chemotherapy and radiation also damage healthy tissue. The toxic side effects most often seenaremielosupressionwhichcompromisesthehostdefenseand mucositis.If a patienthas a temperature over 38.5 degrees C and a granulocyte count of 0.5 0,5 X 10 /I or less we define this as febrile neutropenia. Beside the host factors the type of chemotherapy also determines the risk of neutropenia and febrile neutropenia. Types of chemotherapy that are used today in the treatment of solid tumors are: standard chemotherapy, intensive chemotherapy with growth factors support, high dose chemotherapy with the support of autologous bone marrow transplantation or peripheral blood stem cells and growth factors, high dose sequential chemotherapy with the support of peripheral blood stem cells and growth factors. Febrile neutropenia can also occur in patient receiving radiotherapy as total body irradiation (as mieloablative therapy with bone marrow or stem cell support), after combined chemo and radiotherapy and rarely after irradiation only when at least 50 a/o of bone marrow is irradiated.
Deskriptorji		ANTINEOPLASTIC AGENTS RADIOTHERAPY NEUTROPENIA